Is GBS Inc. (GBS) a Buy, Sell, or Hold?
NASDAQ : GBS
GBS Inc.
$0.4732 USD
-$0.01 (-1.58%)
- Volume
- 9.03K
- Average Volume
- 52.65K
- Market Capitalization
- $433.58K
- P/E Ratio
- -0.18
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.89
- Year Low
- $0.36
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.11
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Harry Simeonidis |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | GBS |
| CUSIP | 36151G709 |
| CIK | 0001725430 |
| Web | https://gbs.inc |
| Phone | 646 828 8258 |
| Currency | USD |
| Employees | 12 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.21 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.11 |
| Quick Ratio | 1.98 |
| Cash Ratio | 1.49 |
Sales & Book Value
| Annual Sales | $3.05M |
| Price / Sales | 0.36 |
| Cash Flow | -7.17 |
| Price / Cash Flow | -0.12 |
| Price / Book | 0.39 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$2 |
| Trailing P/E Ratio | -0.18 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$10.57M |
| Net Margin | -296.76% |
| Pretax Margin | -297.48% |
| Return on Equity | -174.16% |
| Return on Assets | -78.13% |
Financials Score
| AltmanZ Score | -7.29 |
| Piotroski Score | 5.00 |
| Working Capital | 5.14M |
| Total Assets | 14.86M |
| Ebit | -5.94M |
| Market Cap | 433.58K |
| Total Liabilities | 6.11M |
Poll Results
About GBS Inc. (NASDAQ:GBS) Stock
Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, N ... ew York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
2026-05-27 03:00:00
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
2026-05-25 23:00:00
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
2026-05-20 16:33:00
Filing date: May 20, 2026GAAP diluted EPS was $11.09, which is higher than the estimated EPS of $10.65.Revenue was $8,558 million, which is below the estimated
2026-05-19 03:00:00
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
2026-05-11 10:00:00
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.
Frequently Asked Questions
-
What is the current GBS Inc. (GBS) stock price?
-
GBS Inc.(NASDAQ:GBS) stock price is $0.4732 in the last trading session. During the trading session, GBS stock reached the peak price of $2.89 while $0.36 was the lowest point it dropped to. The percentage change in GBS stock occurred in the recent session was --1.58% while the dollar amount for the price change in GBS stock was -$0.01.
-
GBS's industry and sector of operation?
-
The NASDAQ listed GBS is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of GBS?
-
Harry Simeonidis | Pres of Asia Pacific
Spiro Kevin Sakiris | Chief Financial Officer
Victoria Gavrilenko | Operations Mang.
Stephen Constantine Boyages | Interim Chief Executive Officer & Chairman
Alex Arzeno | Vice President of Investor Relations -
How many employees does GBS have?
-
Number of GBS employees currently stands at 12. GBS operates from 708 3rd Avenue, New York City, NY 10019, US.
-
Link for GBS official website?
-
Official Website of GBS is: https://gbs.inc
-
How do I contact GBS?
-
GBS could be contacted at phone #646 828 8258 and can also be accessed through its website. GBS operates from 708 3rd Avenue, New York City, NY 10019, US.
-
How many shares of GBS are traded daily?
-
The average number of GBS shares traded daily for last 3 months was 52.65K.
-
What is the market cap of GBS currently?
-
The market value of GBS currently stands at $433.58K with its latest stock price at $0.4732